Follow Our Live Coverage of COVID-19 Developments

Mediterranean Eating Plan May Help Keep T2DM Patients Off Meds

Med-EatPlan plus extra virgin olive oil linked to lower risk for starting first glucose-lowering medication

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, Aug. 2, 2019 (HealthDay News) -- A Mediterranean eating plan (Med-EatPlan) plus extra virgin olive oil (EVOO) may delay the need for first glucose-lowering medication among participants with type 2 diabetes, according to a study published in the August issue of Diabetes Care.

F. Javier Basterra-Gortari, M.D., Ph.D., from the University of Navarra in Pamplona, Spain, and colleagues randomly assigned 3,230 participants from the Prevención con Dieta Mediterrànea (PREDIMED) trial with type 2 diabetes to the Med-EatPlan supplemented with EVOO, Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan. Two outcomes were assessed: (1) introduction of the first glucose-lowering medication (oral or injectable) for participants on lifestyle management at enrollment and (2) insulin initiation.

After a median follow-up of 3.2 years, the researchers found that after adjustment for baseline characteristics and propensity scores, the hazard ratios for starting a first glucose-lowering medication were 0.78 (95 percent confidence interval [CI], 0.62 to 0.98) and 0.89 (95 percent CI, 0.71 to 1.12) for Med-EatPlan + EVOO and Med-EatPlan + nuts, respectively, versus control. After a median follow-up of 5.1 years, the adjusted hazard ratios for starting insulin treatment were 0.87 (95 percent CI, 0.68 to 1.11) and 0.89 (95 percent CI, 0.69 to 1.14) for Med-EatPlan + EVOO and Med-EatPlan + nuts, respectively, versus the control eating plan.

"Our study results show that PREDIMED participants with type 2 diabetes who underwent an intervention with an energy-unrestricted MedEatPlan + EVOO had significantly lower rates of initiation of glucose-lowering medications," the authors write.

Several authors disclosed financial ties to the biopharmaceutical and nutrition industries.

Abstract/Full Text

Last Updated: